<i>TP53</i> Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy

<i>TP53</i> Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy

Background: Identification of prognostic biomarkers in cancers is a crucial step to improve overall survival (OS). Although mutations in <i>tumour protein 53</i> (<i>TP53</i>) is prevalent in astrocytoma, the prognostic effects of <i>TP53</i> mutation are unclear....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Humaira Noor, Nancy E. Briggs, Kerrie L. McDonald, Jeff Holst, Orazio Vittorio
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
<i>TP53</i> mutation
low-grade glioma
LGG
<i>MGMT</i> methylation
<i>YAP1</i>
chemosensitivity
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/45f3e58e52dd470a99b0524811570245
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/45f3e58e52dd470a99b0524811570245

Ejemplares similares